Log in

NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

$11.00
-0.45 (-3.93 %)
(As of 03/29/2020 02:12 PM ET)
Today's Range
$10.51
Now: $11.00
$11.30
50-Day Range
$8.08
MA: $13.82
$17.57
52-Week Range
$7.00
Now: $11.00
$18.45
Volume149,408 shs
Average Volume314,412 shs
Market Capitalization$384.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Read More
Xenon Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.83 million
Book Value$2.99 per share

Profitability

Net Income$-41,600,000.00

Miscellaneous

Employees89
Market Cap$384.56 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.


Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

How has Xenon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENE shares have decreased by 13.5% and is now trading at $11.00. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Xenon Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenon Pharmaceuticals.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Xenon Pharmaceuticals.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) issued its quarterly earnings data on Monday, March, 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by $0.54. The biopharmaceutical company earned $3.33 million during the quarter, compared to analyst estimates of $25 million. View Xenon Pharmaceuticals' earnings history.

What price target have analysts set for XENE?

4 analysts have issued 1 year target prices for Xenon Pharmaceuticals' shares. Their forecasts range from $18.00 to $25.00. On average, they expect Xenon Pharmaceuticals' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View analysts' price targets for Xenon Pharmaceuticals.

Has Xenon Pharmaceuticals been receiving favorable news coverage?

News articles about XENE stock have been trending extremely negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutXenon Pharmaceuticals.

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 591,300 shares, an increase of 29.8% from the February 27th total of 455,400 shares. Based on an average daily volume of 261,900 shares, the days-to-cover ratio is presently 2.3 days. Currently, 2.6% of the shares of the stock are sold short. View Xenon Pharmaceuticals' Current Options Chain.

Who are some of Xenon Pharmaceuticals' key competitors?

What other stocks do shareholders of Xenon Pharmaceuticals own?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:
  • Simon Neil Pimstone, Chief Executive Officer & Director
  • Ian C. Mortimer, President, Chief Financial Officer & Secretary
  • Ernesto Aycardi, Chief Medical Officer
  • Robin Sherrington, Executive VP-Business & Corporate Development
  • Charles J. Cohen, Vice President-Biological Sciences

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (7.53%), NEA Management Company LLC (3.83%), Point72 Asset Management L.P. (3.31%), Renaissance Technologies LLC (2.30%), Parkman Healthcare Partners LLC (2.27%) and Granite Point Capital Management L.P. (1.05%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View institutional ownership trends for Xenon Pharmaceuticals.

Which major investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Granite Point Capital Management L.P., Russell Investments Group Ltd., Bank of New York Mellon Corp, California Public Employees Retirement System, and Bank of Montreal Can. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab, and Simon N Pimstone. View insider buying and selling activity for Xenon Pharmaceuticals.

Which major investors are buying Xenon Pharmaceuticals stock?

XENE stock was purchased by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, NEA Management Company LLC, Ikarian Capital LLC, BVF Inc. IL, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Marshall Wace LLP, and Cubist Systematic Strategies LLC. View insider buying and selling activity for Xenon Pharmaceuticals.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $11.00.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $384.56 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe. View additional information about Xenon Pharmaceuticals.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]


MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  289 (Vote Underperform)
Total Votes:  637
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Elliott Wave Theory

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel